Do analysts recommend SLGL or DRCT?

Sol-Gel Technologies presently has a consensus price target of $197.50, suggesting a potential upside of 124.60%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Direct Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SLGL or DRCT?

In the previous week, Direct Digital had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Direct Digital and 4 mentions for Sol-Gel Technologies. Direct Digital's average media sentiment score of 0.90 beat Sol-Gel Technologies' score of 0.80 indicating that Direct Digital is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Direct Digital 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, SLGL or IVA?

Sol-Gel Technologies has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sol-Gel Technologies $19.39M 12.74 -$6.13M -$0.34 N/A Inventiva $5.07M 188.05 -$400.67M N/A N/A

Does the media prefer SLGL or IVA?

In the previous week, Sol-Gel Technologies had 2 more articles in the media than Inventiva. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 2 mentions for Inventiva. Inventiva's average media sentiment score of 1.45 beat Sol-Gel Technologies' score of 0.80 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMPH or SLGL?

In the previous week, Amphastar Pharmaceuticals had 14 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 18 mentions for Amphastar Pharmaceuticals and 4 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.80 beat Amphastar Pharmaceuticals' score of 0.49 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 5 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TBPH or SLGL?

In the previous week, Theravance Biopharma had 4 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 8 mentions for Theravance Biopharma and 4 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.80 beat Theravance Biopharma's score of 0.50 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sol-Gel Technologies (SLGL) Competitors

$87.93 +3.89 (+4.63%)

As of 11:20 AM Eastern

Compare

SLGL vs. DRCT, TRAW, IVA, AMPH, and TBPH

Should you buy Sol-Gel Technologies stock or one of its competitors? Sol-Gel Technologies's main competitors and comparable companies include Direct Digital (DRCT), Traws Pharma (TRAW), Inventiva (IVA), Amphastar Pharmaceuticals (AMPH), and Theravance Biopharma (TBPH). Companies are selected based on similarities in market, industry, and size.

How does Sol-Gel Technologies compare to Direct Digital?

Sol-Gel Technologies (NASDAQ:SLGL) and Direct Digital (NASDAQ:DRCT) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 4.0% of Direct Digital shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 25.6% of Direct Digital shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sol-Gel Technologies has a net margin of -5.66% compared to Direct Digital's net margin of -74.38%. Direct Digital's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Direct Digital	-74.38%	N/A	-67.05%

Sol-Gel Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Direct Digital has a beta of 5.33, indicating that its share price is 433% more volatile than the broader market.

Sol-Gel Technologies has higher earnings, but lower revenue than Direct Digital. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.74	-$6.13M	-$0.34	N/A
Direct Digital	$34.69M	0.06	-$18.95M	-$201.62	N/A

In the previous week, Direct Digital had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Direct Digital and 4 mentions for Sol-Gel Technologies. Direct Digital's average media sentiment score of 0.90 beat Sol-Gel Technologies' score of 0.80 indicating that Direct Digital is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Direct Digital	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sol-Gel Technologies presently has a consensus price target of $197.50, suggesting a potential upside of 124.60%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Direct Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sol-Gel Technologies beats Direct Digital on 11 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Traws Pharma?

Sol-Gel Technologies (NASDAQ:SLGL) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 7.6% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Traws Pharma. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.89 beat Sol-Gel Technologies' score of 0.80 indicating that Traws Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Sol-Gel Technologies	Positive
Traws Pharma	Very Positive

Sol-Gel Technologies currently has a consensus price target of $197.50, indicating a potential upside of 124.60%. Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 70.65%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Traws Pharma has lower revenue, but higher earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.74	-$6.13M	-$0.34	N/A
Traws Pharma	$2.79M	3.18	$9.17M	-$1.69	N/A

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Traws Pharma	N/A	-913.18%	-133.88%

Sol-Gel Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Summary

Sol-Gel Technologies beats Traws Pharma on 12 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Inventiva?

Sol-Gel Technologies (NASDAQ:SLGL) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Sol-Gel Technologies had 2 more articles in the media than Inventiva. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 2 mentions for Inventiva. Inventiva's average media sentiment score of 1.45 beat Sol-Gel Technologies' score of 0.80 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sol-Gel Technologies has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Sol-Gel Technologies has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.74	-$6.13M	-$0.34	N/A
Inventiva	$5.07M	188.05	-$400.67M	N/A	N/A

Inventiva has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Inventiva's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Inventiva	N/A	N/A	N/A

Sol-Gel Technologies presently has a consensus target price of $197.50, indicating a potential upside of 124.60%. Inventiva has a consensus target price of $16.56, indicating a potential upside of 260.69%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Inventiva beats Sol-Gel Technologies on 9 of the 15 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Amphastar Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals had 14 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 18 mentions for Amphastar Pharmaceuticals and 4 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.80 beat Amphastar Pharmaceuticals' score of 0.49 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	5 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Amphastar Pharmaceuticals currently has a consensus price target of $22.00, suggesting a potential upside of 6.18%. Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 124.60%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Amphastar Pharmaceuticals has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.22	$98.09M	$1.69	12.26
Sol-Gel Technologies	$19.39M	12.74	-$6.13M	-$0.34	N/A

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Sol-Gel Technologies' net margin of -5.66%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Summary

Amphastar Pharmaceuticals beats Sol-Gel Technologies on 9 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, Theravance Biopharma had 4 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 8 mentions for Theravance Biopharma and 4 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.80 beat Theravance Biopharma's score of 0.50 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Theravance Biopharma currently has a consensus price target of $19.40, suggesting a potential upside of 14.56%. Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 124.60%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Theravance Biopharma has a net margin of 51.58% compared to Sol-Gel Technologies' net margin of -5.66%. Theravance Biopharma's return on equity of -0.78% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.78%	-0.47%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Theravance Biopharma has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Theravance Biopharma has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31M	8.43	$105.89M	$1.01	16.77
Sol-Gel Technologies	$19.39M	12.74	-$6.13M	-$0.34	N/A

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Theravance Biopharma beats Sol-Gel Technologies on 9 of the 16 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLGL vs. The Competition

Export

Metric	Sol-Gel Technologies	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$247.45M	$11.70B	$6.97B	$13.06B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-258.99	783.85	269.56	25.27
Price / Sales	12.74	747.98	596.64	100.41
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	10.74	10.66	13.00	6.30
Net Income	-$6.13M	$2.77B	$3.45B	$347.83M
7 Day Performance	-0.08%	-0.25%	0.57%	0.94%
1 Month Performance	16.64%	-0.10%	1.22%	0.90%
1 Year Performance	476.62%	160.98%	66.67%	20.40%

Sol-Gel Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLGL Sol-Gel Technologies	3.9094 of 5 stars	$87.93 +4.6%	$197.50 +124.6%	+443.9%	$247.45M	$19.39M	N/A	50	News Coverage Upcoming Earnings
DRCT Direct Digital	0.8931 of 5 stars	$2.67 -1.1%	N/A	-97.3%	$1.98M	$34.69M	N/A	60	Earnings Report Gap Up
TRAW Traws Pharma	3.2391 of 5 stars	$0.55 +17.3%	$1.00 +80.7%	-63.4%	$8.38M	$2.79M	N/A	17	Positive News Gap Up
IVA Inventiva	2.9508 of 5 stars	$4.51 +6.1%	$16.56 +267.1%	+14.4%	$936.77M	$5.07M	N/A	100	Positive News
AMPH Amphastar Pharmaceuticals	3.0784 of 5 stars	$19.90 -1.6%	$22.00 +10.6%	-33.8%	$877.39M	$719.89M	11.99	1,976	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLGL) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, IVA, AMPH, and TBPH

How does Sol-Gel Technologies compare to Direct Digital?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Summary

How does Sol-Gel Technologies compare to Inventiva?

Summary

How does Sol-Gel Technologies compare to Amphastar Pharmaceuticals?

Summary

How does Sol-Gel Technologies compare to Theravance Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, IVA, AMPH, and TBPH

How does Sol-Gel Technologies compare to Direct Digital?

Do insiders and institutionals have more ownership in SLGL or DRCT?

Is SLGL or DRCT more profitable?

Which has more volatility and risk, SLGL or DRCT?

Which has better valuation & earnings, SLGL or DRCT?

Does the media favor SLGL or DRCT?

Do analysts recommend SLGL or DRCT?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Do institutionals and insiders hold more shares of SLGL or TRAW?

Does the media prefer SLGL or TRAW?

Do analysts recommend SLGL or TRAW?

Which has better earnings & valuation, SLGL or TRAW?

Is SLGL or TRAW more profitable?

Which has more volatility & risk, SLGL or TRAW?

Summary

How does Sol-Gel Technologies compare to Inventiva?

Does the media prefer SLGL or IVA?

Which has more volatility and risk, SLGL or IVA?

Which has higher valuation & earnings, SLGL or IVA?

Is SLGL or IVA more profitable?

Do analysts recommend SLGL or IVA?

Do institutionals & insiders hold more shares of SLGL or IVA?

Summary

How does Sol-Gel Technologies compare to Amphastar Pharmaceuticals?

Which has more risk and volatility, AMPH or SLGL?

Does the media refer more to AMPH or SLGL?

Do insiders and institutionals hold more shares of AMPH or SLGL?

Do analysts prefer AMPH or SLGL?

Which has preferable earnings and valuation, AMPH or SLGL?

Is AMPH or SLGL more profitable?

Summary

How does Sol-Gel Technologies compare to Theravance Biopharma?

Does the media refer more to TBPH or SLGL?

Do analysts rate TBPH or SLGL?

Is TBPH or SLGL more profitable?

Which has more volatility and risk, TBPH or SLGL?

Which has higher valuation and earnings, TBPH or SLGL?

Do insiders & institutionals hold more shares of TBPH or SLGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools